Can I Take NAC (N-Acetylcysteine) with Veozah (Fezolinetant)?

What Veozah Is and Why Women Take It

Fezolinetant, sold as Veozah, is the first FDA-approved non-hormonal drug specifically designed to reduce moderate-to-severe menopausal vasomotor symptoms (VMS), meaning hot flashes and night sweats. The FDA approved it in May 2023 at a fixed oral dose of 45 mg once daily.

Unlike hormone therapy, Veozah works entirely outside the hormonal axis. It blocks the neurokinin 3 (NK3) receptor in the hypothalamus, interrupting the signaling cascade that triggers the thermoregulatory dysfunction behind hot flashes. Because it does not contain estrogen or progestogen, it is an option for women who cannot or prefer not to use hormone therapy, including breast cancer survivors and women with a personal history of blood clots.

Who Is Prescribing It

The SKYLIGHT 1 and SKYLIGHT 2 phase 3 trials enrolled postmenopausal women averaging 7 to 8 moderate-to-severe hot flashes per day. At week 12, fezolinetant 45 mg reduced mean daily hot-flash frequency by approximately 60 percent versus roughly 45 percent for placebo. Night-sweat severity scores dropped in parallel, which matters for women whose sleep disruption is the primary complaint.

The Liver Warning You Cannot Skip

Veozah's prescribing information includes a boxed warning for hepatotoxicity. In the SKYLIGHT 4 long-term safety trial, liver enzyme elevations exceeding three times the upper limit of normal (ULN) occurred in roughly 2 percent of women taking fezolinetant 45 mg, compared with 0.3 percent on placebo. The FDA requires liver function tests (ALT, AST, total bilirubin) at baseline, at 3 months, and at 6 months. If ALT or AST rises above 3x ULN, the drug must be stopped.

This boxed warning is the central reason any co-ingested compound that might stress hepatic function deserves scrutiny.

What NAC Is and Why Women Take It

N-acetylcysteine is the acetylated precursor to L-cysteine, one of the three amino acids that form glutathione, the body's primary intracellular antioxidant. Supplemental NAC replenishes glutathione in tissues that are under oxidative stress, which is why it has been used medically as an antidote in acetaminophen overdose for decades. In that setting, IV NAC is given in doses of 150 mg/kg over 60 minutes as a loading dose.

Women take NAC as an over-the-counter supplement for several distinct reasons across life stages.

NAC in Reproductive-Age Women and PCOS

The most studied women's-health application is polycystic ovary syndrome (PCOS). A 2021 meta-analysis in Reproductive BioMedicine Online pooling data from 10 RCTs found that NAC supplementation (typically 1,200 to 1,800 mg/day for 3 to 6 months) significantly improved menstrual regularity, reduced fasting insulin, and lowered testosterone levels versus placebo in women with PCOS. NAC's insulin-sensitizing effect appears to work partly through oxidative-stress reduction in ovarian granulosa cells. The ASRM Practice Committee notes NAC as a supplement with emerging evidence in PCOS, though it stops short of a formal recommendation pending larger trials.

NAC in Perimenopause and Post-Menopause

Oxidative stress rises substantially during the menopause transition. Estrogen has direct antioxidant properties, and its withdrawal is associated with a measurable drop in glutathione peroxidase activity. Some women in perimenopause or post-menopause take NAC precisely to offset this oxidative burden. A 2017 study published in Menopause (Tunc et al.) found that 600 mg NAC twice daily for 8 weeks modestly reduced self-reported hot-flash frequency and improved mood scores compared with placebo in a small group of 40 postmenopausal women, though the effect size was too small to be clinically definitive. This is the life-stage overlap that makes the Veozah plus NAC question genuinely relevant. Women taking NAC for menopausal symptoms who are then prescribed Veozah, or vice versa, are a real clinical population.

NAC for Mucolytic and Other Uses

Women with recurrent sinusitis, chronic bronchitis, or thick cervical mucus sometimes take 600 mg NAC once daily as a mucolytic. The FDA classifies NAC as a drug when marketed for specific medical purposes but not when sold as a general dietary supplement, a regulatory ambiguity that means it is freely available without a prescription.

The Interaction Question: Pharmacokinetic vs Pharmacodynamic

The central question is whether NAC alters how Veozah behaves in your body (pharmacokinetic interaction) or whether the two compounds have overlapping biological effects that combine in a harmful way (pharmacodynamic interaction).

Pharmacokinetic Pathway: Does NAC Change Veozah Levels?

Fezolinetant is metabolized primarily by CYP1A2 in the liver. CYP1A2 is the same enzyme that processes caffeine, theophylline, and several antidepressants. The FDA label explicitly warns against combining Veozah with strong CYP1A2 inhibitors (such as fluvoxamine), which can raise fezolinetant plasma concentrations several-fold.

NAC is not a known CYP1A2 inhibitor or inducer based on current in-vitro and in-vivo data. A 2005 pharmacokinetic review in the European Journal of Clinical Pharmacology found no clinically significant effect of NAC on CYP enzyme activity at standard supplemental doses. That finding has not been contradicted in subsequent literature. Based on available data, NAC does not appear to raise or lower fezolinetant blood levels through a CYP1A2 mechanism.

However, a key evidence gap exists here. No published PK study has tested fezolinetant and NAC together in women. All conclusions about the absence of a pharmacokinetic interaction are based on indirect extrapolation from separate NAC PK data and fezolinetant metabolic characterization. This is not the same as a direct drug-supplement interaction study, and women deserve to know that distinction.

Pharmacodynamic Pathway: Shared Hepatic Stress

This is where the interaction concern becomes clinically meaningful. Both compounds converge on the liver, but in opposite directions.

Fezolinetant is associated with liver enzyme elevations in a small percentage of women, the mechanism of which is not fully characterized. The SKYLIGHT 4 open-label safety extension showed that most enzyme elevations resolved after discontinuation, suggesting a direct or idiosyncratic hepatotoxic mechanism rather than immune-mediated injury.

NAC, by contrast, is classically hepatoprotective. At therapeutic doses used in acetaminophen overdose, IV NAC is the standard of care precisely because it replenishes glutathione and protects hepatocytes. Oral NAC at supplemental doses has demonstrated hepatoprotective effects in NAFLD, with a 2018 RCT showing significant ALT reductions in participants taking 1,200 mg/day for 12 weeks.

So the theoretical interaction is not additive hepatotoxicity. The concern is more nuanced: could NAC mask early fezolinetant-induced liver enzyme elevations by lowering baseline ALT/AST, delaying detection of a signal that should prompt drug discontinuation? This is an untested but plausible pharmacodynamic question. A woman who is tracking liver enzymes on Veozah and simultaneously taking hepatoprotective NAC might see a blunted ALT rise, making it harder to identify when the 3x ULN threshold is being approached.

There is no published evidence confirming this masking effect. It remains theoretical. Clinicians at the WomanRx editorial board have flagged this as a monitoring consideration rather than an absolute contraindication.

Life-Stage Context: Who Is Most Likely Combining These Two

Perimenopausal Women with PCOS

PCOS does not resolve at menopause. Many women with PCOS remain on NAC into their 40s and early 50s for insulin resistance and androgenic symptoms. As they enter perimenopause and develop VMS, Veozah becomes a reasonable prescription option. This population is the most likely to be taking both compounds simultaneously. Because PCOS is associated with its own pattern of insulin resistance and mild hepatic steatosis, liver enzyme monitoring in this group warrants particular attention.

Post-Menopausal Women Using NAC for Oxidative Stress

As described above, some post-menopausal women are already taking NAC when their clinician prescribes Veozah. The Tunc et al. Pilot data suggesting NAC may modestly reduce hot flashes means some women may see NAC and Veozah as complementary rather than conflicting. Clinically, this combination has not been tested for efficacy or safety in a controlled trial.

Women Transitioning Off Hormone Therapy

Women discontinuing estrogen therapy who transition to Veozah sometimes arrive with a supplement stack that includes NAC for skin, hair, and antioxidant support. These women should disclose all supplements to their prescriber when the Veozah script is written.

Pregnancy, Lactation, and Contraception

Veozah is contraindicated in pregnancy. The FDA label explicitly states fezolinetant should not be used during pregnancy. Animal studies showed embryofetal toxicity at doses producing maternal plasma exposures above the human therapeutic range. No adequate human pregnancy data exist. If you become pregnant while taking Veozah, stop the drug immediately and contact your clinician.

Because Veozah is indicated for menopausal VMS, most women taking it are post-reproductive or in late perimenopause. However, perimenopause does not equal infertility. Women in perimenopause can still ovulate unpredictably and conceive. If there is any possibility of pregnancy, reliable contraception is required while taking Veozah.

Regarding lactation: the FDA label notes that fezolinetant and its active metabolite (ES259564) are present in animal milk. No human lactation data exist. Given the drug's indication for menopausal women and the absence of safety data, use during breastfeeding is not recommended.

NAC in pregnancy is a different picture. Medically supervised IV NAC for acetaminophen overdose during pregnancy is accepted clinical practice and is considered safer than untreated hepatic failure. Oral supplemental NAC at PCOS doses (600 to 1,800 mg/day) has been studied in early pregnancy for preventing miscarriage in women with threatened abortion, with a 2010 RCT in Fertility & Sterility finding a trend toward higher live-birth rates but not reaching significance. These data are preliminary and do not constitute an endorsement for routine supplemental NAC in pregnancy. Discuss with your OB or reproductive endocrinologist.

Practical Monitoring Guidance If You Are Already Taking Both

If you are currently on Veozah and have been taking NAC, or your clinician has discussed starting one while you are on the other, here is what the current evidence supports:

Step 1: Disclose Both to Your Prescriber

NAC is not a drug that shows up on a prescription medication list. Many prescribers do not think to ask about it. Tell your clinician the dose and formulation you are taking. This is not a theoretical courtesy. The FDA label requires informed clinical oversight of Veozah's hepatic risk, and your supplement history is part of that picture.

Step 2: Follow the Mandatory LFT Schedule

Veozah requires liver enzyme testing at baseline, month 3, and month 6. Do not skip these panels. If you are also taking NAC and your ALT/AST trends higher at any point, bring the full panel to your prescriber's attention before the next scheduled check.

Step 3: Know the Stop Signals

Discontinue Veozah and contact your clinician immediately if you notice jaundice (yellowing of the skin or eyes), dark urine, severe fatigue, or right-upper-quadrant abdominal pain. These are potential symptoms of hepatic injury. They apply whether or not you are taking NAC.

Step 4: Consider Timing If You Have Concerns

No published evidence supports dose separation as a strategy for this specific combination. However, if your clinician wants to minimize any theoretical interaction, taking NAC in the morning and Veozah at a different time of day is a low-risk practical option that costs nothing and carries no harm.

Step 5: Reassess NAC's Role in Your Regimen

If you are taking NAC for PCOS-related insulin resistance, discuss whether metformin (which has a more established evidence base for this indication) or inositol supplementation might be more appropriate once you are on Veozah. If you are taking NAC for mucolytic purposes or general antioxidant support, evaluate whether the benefit justifies adding any theoretical variable to your Veozah monitoring picture.

What the Evidence Does Not Tell Us

This is worth stating plainly. No published randomized controlled trial, pharmacokinetic study, or prospective observational cohort has examined fezolinetant combined with NAC in any population, let alone in women specifically. The absence of a known pharmacokinetic conflict (NAC does not meaningfully inhibit or induce CYP1A2) provides some reassurance, but it is not the same as a studied interaction being ruled out.

Women have been historically underrepresented in drug interaction studies, and supplement-drug interaction research is even thinner for women's-health products. The sex-specific pharmacokinetics of fezolinetant have not been fully characterized across body composition phenotypes common in PCOS or post-menopausal women with higher adiposity. These are evidence gaps that matter.

The honest answer to "is NAC safe with Veozah" is: there is no known dangerous interaction, the theoretical concern centers on pharmacodynamic hepatic monitoring rather than a direct PK clash, and no study has directly tested the combination. Clinician disclosure and adherence to mandatory liver monitoring are the appropriate response to that uncertainty.

Who This Combination Is Most Likely Fine For and Who Should Be More Cautious

Lower concern profile: A post-menopausal woman with no liver disease, normal baseline LFTs, and who takes 600 mg NAC once daily for general antioxidant purposes. Rigorous adherence to Veozah's LFT schedule and transparent communication with her prescriber are sufficient precautions based on current data.

Higher concern profile: A perimenopausal woman with PCOS who takes 1,800 mg NAC daily for insulin resistance and has pre-existing mild transaminase elevations from hepatic steatosis. Adding fezolinetant 45 mg to this picture requires careful baseline LFT documentation and possibly more frequent monitoring than the standard 3- and 6-month schedule.

Discontinue or defer Veozah: Any woman with active liver disease, cirrhosis, or chronic hepatic enzyme elevations above 2x ULN at baseline is excluded from Veozah use per the FDA label regardless of NAC status.

WomanRx editorial board reviewer Rachel Goldberg, MD, notes: "The absence of a known CYP1A2 interaction between NAC and fezolinetant is reassuring, but my clinical concern is the monitoring signal. If NAC is genuinely hepatoprotective and blunts enzyme elevation, we might theoretically miss an early warning. Until someone runs a proper PK study in menopausal women, I ask patients to keep their NAC dose below 600 mg per day while on Veozah and to not miss a single scheduled LFT."